Sector
PharmaceuticalsOpen
₹40.34Prev. Close
₹40.34Turnover(Lac.)
₹0Day's High
₹40.34Day's Low
₹39.5452 Week's High
₹64.552 Week's Low
₹27.5Book Value
₹15.07Face Value
₹10Mkt Cap (₹ Cr.)
24.79P/E
101.38EPS
0.39Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 6.27 | 6.27 | 6.27 | 6.27 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 2.99 | 2.11 | -1.07 | -0.91 |
Net Worth | 9.26 | 8.38 | 5.2 | 5.36 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 0 | 1.56 | 4.7 | 0.76 |
yoy growth (%) | -99.94 | -66.81 | 517.42 | -99.1 |
Raw materials | 0 | -1.49 | -4.31 | -0.42 |
As % of sales | 0 | 95.54 | 91.7 | 55.85 |
Employee costs | -0.21 | -0.19 | -0.19 | -0.46 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | -0.24 | -0.44 | -0.75 | -4.35 |
Depreciation | 0 | 0 | -0.06 | -0.63 |
Tax paid | 0 | 0 | -0.03 | -0.53 |
Working capital | -0.24 | 0.02 | -6.06 | 8.23 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -99.94 | -66.81 | 517.42 | -99.1 |
Op profit growth | -21.72 | 11.99 | -66.36 | -47.07 |
EBIT growth | -45.37 | -10.56 | -77.2 | -44.5 |
Net profit growth | -45.37 | -3,990.31 | -99.88 | -207.52 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.35 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493.2 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,483.15 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.4 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,167.95 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Independent Director
Devendra J Shrimanker
Independent Director
Prajakta Shidhore
Non Executive Director
Arun Goenka
Non Executive Director
Purusottam Kejriwal
Company Sec. & Compli. Officer
Divya Desai
Non Executive Director
Kostuv Kejriwal
Independent Director
Haroon Hasan Siddiqi
509 Western Edge I Western edg,
Express Highway warehouse,
Maharashtra - 400066
Tel: -
Website: http://www.pentokey.com
Email: investors@pentokey.com
Plot No B-5 MIDC,
Part B Cross Lane, Marol Andheri(E),
Mumbai-400093
Tel: 91-22-6671 2151
Website: www.dfssl.com
Email: marketing@dfssl.com/investorsqry@dfssl.com
Summary
Pentokey Organy (India) Ltd was incorporated on November 26, 1986. The Company is engaged in the trading of Pharmaceutical products such as Acetic Acid, Ethyl Acetate and Acetaldehyde. Ethyl Acetate ...
Read More
Reports by Pentokey Organy (India) Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.